Transdermal Allergy Immunotherapy Study Shows Promise As An Alternative to Injections
Final results from the RELIEF Study Released
Topical Analgesics Reduce Opioid Usage over 3 and 6-months
“Traditional Allergy Immunotherapy consists of multiple years of Injections (sub-cutaneous immunotherapy- (SCIT)). We now have preliminary evidence that supplying allergens through topical administration shows a decrease in IgE levels and may prove to be a viable alternative to allergy shots and the millions of people who are allergy sufferers. We are conducting more clinical trials and excited to expand on these initial results.”
Peter Hurwitz
President, Clarity Science LLC
Co-Author
“The data from our recent studies showed that there are alternative pain management treatment options available for healthcare professionals to help address a patient’s pain. These options may lead to a reduced focus on Opioid prescribing and other oral analgesics and their side effects and have a significant and positive impact on patient care and outcomes.”
Peter Hurwitz
President, Clarity Science LLC
See informative results from our studies.
Current Scar Study
TARGET
(TopicAl Silicone in RestorinG Scars and Burn Tissue – Evaluating Therapy)
Positive interim TARGET Results have been presented at leading conferences, including the 7th Joint Meeting of the European Tissue Repair Society & the Wound Healing Society held in Copenhagen, Denmark, among others.
Results from an interim analysis of our TARGET study (a scar and burn treatment study) show that adults using a prescribed topical scar and burn cream reported:

Reduced scar/burn size as measured by clinicians and as perceived by patients.

Reduced itching.

Reduced scar/burn interference with general activity, mood, sleep, and life enjoyment.

Reduced pain medication use.
Closed Pain Study
OPERA
(Optimizing Patient Experience and Response to Topical Analgesics)
Positive interim OPERA Results have been presented at important conferences, including the 4th Annual International Conference on Opioids held at Harvard Medical School, among others.
Results from an interim analysis of our OPERA study (a pain study) show that patients with musculoskeletal and neuropathic pain using a prescribed topical analgesic reported:

Reduced pain severity for patients with neuropathic and musculoskeletal pain.

Reduced pain interference with general activity, mood, sleep, and life enjoyment.

Reduced number of primary pain complaints for arthritis, neuropathy, or radiculopathy.

Reduced use of over-the-counter medications, anti-inflammatory medications, and opioid analgesics.
Conference & Publications Highlights

News & Announcements

Clarity to Exhibit at AAAAI
November 2, 2015

Clarity to Exhibit at AAAAI
November 2, 2015

TARGET Study Data to be Presented at APWCA
February 25, 2016

TARGET Study Data to be Presented at APWCA
February 25, 2016


NIH Study Invitation
November 1, 2015


NIH Study Invitation
November 1, 2015

TARGET Study featured in the Journal of Wound Technology
January 5, 2016

TARGET Study featured in the Journal of Wound Technology
January 5, 2016
A peer-reviewed article of our TARGET study entitled “Patient-Reported Outcomes and Perceptions Following the Use of Compounded Topical Scar/Burn Treatments: Interim Results from an Observational Study,” was accepted for publication by the international Journal of Wound Technology and appears in its January 2016 Special Issue: Scar.Journal of Wound Technology: TARGET Study
Previous
Next